Project Details
| Short title | Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with Mavrilimumab to restore anti-cancer immunity |
|---|---|
| Status | Finished |
| Effective start/end date | 1/01/20 → 30/04/21 |
Funding
- Kiniksa Pharmaceuticals